“…Gene sequencing, supported by biochemical studies, has revealed a number of significant differences between the pyrimidine biosynthetic pathways of Leishmania and mammals: 1) the genes encoding the pyrimidine pathway of Leishmania are syntenic (2-5), whereas the mammalian pyrimidine genes are not; 2) the genes encoding the first three enzymes in Leishmania are dis-crete, unlike the mammalian pathway in which there is a single gene encoding a trifunctional protein (6, 7); 3) the last two enzymes of the pyrimidine biosynthetic pathway are expressed as a single bifunctional protein, designated UMP synthase (UMPS), although the domain order in Leishmania and mammalian cells is reversed (3,8); and 4) the UMP synthase of Leishmania is localized within the glycosome (3), a unique peroxisomal-like organelle that is found uniquely among Leishmania and related parasites (9,10). Genetic ablation of either carbamoyl phosphate synthetase (CPS), the first enzyme of pyrimidine biosynthesis, or UMPS in L. donovani confer pyrimidine auxotrophy that can be circumvented by supplementation of the defined growth medium with uracil, uridine, deoxyuridine, cytidine, or deoxycytidine (3,5). Furthermore, both the ⌬cps and the ⌬umps null mutants exhibit a striking collateral supersensitivity to uracil, which is innocuous to wild type parasites, that is not observed with any of the ribonucleosides (5).…”